Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02979301 · ClinicalTrials.gov registry record · NA

Impact of Low-dose Tamoxifen on BPU

A NA study, sponsored by Mayo Clinic.

Completed
Registry status
NA
Development phase
22
Enrollment target

NCT02979301: Completed NA study, sponsored by Mayo Clinic.

NCT02979301 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02979301, a NA study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
NA
Development phase
22 participants
Enrollment target

Study Summary

The study will examine whether changes in background parenchymal uptake (BPU) on molecular breast imaging (MBI) can be induced by short-term use of low-dose tamoxifen. Women who have previously had high BPU on MBI will be recruited. Participants will take low-dose tamoxifen for a 30-day period, with post-tamoxifen MBI in order to investigate the impact of tamoxifen on BPU.

Interventions

  • DRUG Tamoxifen

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2017-03-01
Est. Completion 2018-11-01
Phase NA

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT02979301

The ClinicalTrials.gov registry entry for NCT02979301 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Tamoxifen is the first listed.

NCT02979301 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02979301 about?

NCT02979301 is a clinical study titled "Impact of Low-dose Tamoxifen on BPU". The study will examine whether changes in background parenchymal uptake (BPU) on molecular breast imaging (MBI) can be induced by short-term use of low-dose tamoxifen. Women who have previously had high BPU on MBI will be recruited. Participants will take low-dose tamoxifen for a 30-day period, with...

What is the current status of trial NCT02979301?

This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2017-03-01. Estimated completion is 2018-11-01.

What interventions are being tested in trial NCT02979301?

The interventions under investigation include: Tamoxifen (DRUG).

Who is sponsoring clinical trial NCT02979301?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.